Despite significant progress in RCC molecular pathology, RCC prognosis is still best evaluated by using traditional parameters, evaluating tumor anatomy and loco-regional extension/systemic dissemination (TNM classification/individual components), tumor histology (nuclear grade, specific subtype, necrosis, lympho-vascular, and collecting system invasion [171]), and clinical status (performance scores, local symptomatology, cachexia, anemia, platelet/neutrophil/lymphocyte count, C-reactive protein, and albumin levels [172,173,174,175,176,177,178]). The gene discussed is CRP; the disease is renal cell carcinoma.